Ocular Therapeutix
Founded Year
2006Stage
IPO | IPOTotal Raised
$53.3MDate of IPO
7/25/2014Market Cap
0.52BStock Price
6.66Revenue
$0000About Ocular Therapeutix
Ocular Therapeutix, formerly I-Therapeutix, is focused on the development and commercialization of ophthalmic therapeutic products using its hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and ReSure Sealant for sealing clear corneal incisions following lens implantation surgery.
Missing: Ocular Therapeutix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ocular Therapeutix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ocular Therapeutix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ocular Therapeutix is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,928 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Ocular Therapeutix Patents
Ocular Therapeutix has filed 17 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Experimental cancer drugs
- Disorders of choroid and retina
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/16/2022 | 4/11/2023 | Diseases of the eye and adnexa, Ophthalmology, Amines, Eye surgery, Blindness | Grant |
Application Date | 2/16/2022 |
|---|---|
Grant Date | 4/11/2023 |
Title | |
Related Topics | Diseases of the eye and adnexa, Ophthalmology, Amines, Eye surgery, Blindness |
Status | Grant |
Latest Ocular Therapeutix News
May 8, 2023
Bedford, Massachusetts, UNITED STATES BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their JMP representative. A live webcast of the fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com . About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and diabetic retinopathy; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, both of which have completed Phase 2 clinical trials. Investors
Ocular Therapeutix Frequently Asked Questions (FAQ)
When was Ocular Therapeutix founded?
Ocular Therapeutix was founded in 2006.
Where is Ocular Therapeutix's headquarters?
Ocular Therapeutix's headquarters is located at 24 Crosby Drive, Bedford.
What is Ocular Therapeutix's latest funding round?
Ocular Therapeutix's latest funding round is IPO.
How much did Ocular Therapeutix raise?
Ocular Therapeutix raised a total of $53.3M.
Who are the investors of Ocular Therapeutix?
Investors of Ocular Therapeutix include Ascension Ventures, Baxter Ventures, SV Health Investors, Versant Ventures, Polaris Partners and 4 more.
Who are Ocular Therapeutix's competitors?
Competitors of Ocular Therapeutix include SynergEyes, MedShape, Powervision, Biomimedica, BioHorizons and 12 more.
Compare Ocular Therapeutix to Competitors
iBalance, Inc. is developing an improved method for completing an orthopedic surgical procedure called high tibial osteotomy. The company aims to provide the surgical tools and implant for this knee malalignment corrective surgery.
Cagenix develops and researches new devices for dental implants. The company's main focus is on providing superstructures for multiple dental implants that is used to restore chewing function and aesthetics for patients.
Realistic Eye aims to provide a more natural appearance for the 750,000 patients in the US with an artificial eye that does not dilate and therefore appears unnatural. RealisticEye achieves these results by introducing a dilating artificial eye.
Medtronic Biomedicus, Inc, Sterile Systems Operation has been providing EtO Sterilization services since 1990. Sterile Systems has four large chambers and a single smaller one. Because the company have chambers of multiple sizes, the company can easily handle loads from one cart to eight pallets. Sterile Systems is owned by Medtronic, a publicly traded medical device manufacturers. The company are able to leverage the benefits of being part of a multi-national corporation, but still offer the kind of customer service and personalized attention users get from design to sterilized product.
Suneva Medical develops differentiated products for the general dermatology and aesthetic markets. The company markets Bellafill, a dermal filler approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, and distensible facial acne scars on the cheek in patients over the age of 21 years. The company was founded in 2009 and is based in San Diego, California.
Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.